Application and progress of albumin-bilirubin grade in hepatocellular carcinoma
10.3760/cma.j.cn115396-20200110-00009
- VernacularTitle:白蛋白-胆红素分级在肝细胞癌中的应用及进展
- Author:
Yifeng WU
1
;
Chaoyong TU
;
Chuxiao SHAO
Author Information
1. 温州医科大学附属第一医院肝胆胰外科 325000
- From:
International Journal of Surgery
2020;47(10):716-720
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma is one of the pathological types of primary liver cancer, and its prognosis is often not ideal. The prognosis of patients with hepatocellular carcinoma is not only closely related to tumor load and general physical status, but also closely related to liver reserve function. Albumin-bilirubin grading (ALBI) is a new model reflecting liver reserve function. In many therapeutic measures, such as surgical resection, liver transplantation, transcatheter arterial chemoembolization, radiofrequency ablation and targeted therapy, its ability to predict the prognosis of patients with hepatocellular carcinoma has been proved to be no less than that of Child-Pugh grade, which is widely used in clinic, and its predictive performance will be further improved when combined with other indexes.Therefore, it has great application value in clinical practice. This article mainly reviews the clinical application of ALBI grade in patients with hepatocellular carcinoma and the progress of research results in recent years.
